What it's for (Indications)
- Verapamil hydrochloride is indicated for the management of various cardiovascular conditions.
- These include the treatment of essential hypertension, where it effectively lowers blood pressure by reducing systemic vascular resistance.
- It is also indicated for the long-term management of angina pectoris, including chronic stable angina, unstable angina (preinfarction angina), and vasospastic angina (Prinzmetal's angina), by improving myocardial oxygen supply and demand balance.
- Furthermore, verapamil is utilized in the management of supraventricular tachyarrhythmias, such as paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation, and atrial flutter, primarily for the rapid control of ventricular rate.
- Its effectiveness in these conditions stems from its ability to modulate calcium influx, thereby influencing cardiac contractility, vascular tone, and electrical conduction within the heart.
- The choice of formulation (immediate-release vs.
- extended-release) and dosage depends on the specific indication and patient-specific factors, requiring careful clinical assessment and titration.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of verapamil hydrochloride is highly individualized based on the patient's specific indication, response, and tolerability, with both immediate-release (IR) and extended-release (ER) formulations available. For hypertension, typical initial oral IR doses range from 80 mg three times daily, which can be titrated up to 480 mg/day in divided doses. For ER formulations, initial doses are commonly 180 mg once daily, adjusted based on blood pressure response up to 480 mg once daily. In angina, IR verapamil usually starts at 80 mg three times daily, with a maximum daily dose of 480 mg. For acute supraventricular tachyarrhythmias, intravenous (IV) verapamil may be administered, typically as a 5-10 mg bolus, followed by oral maintenance therapy. Elderly patients and those with hepatic impairment require lower initial doses and slower titration due to reduced drug clearance and increased bioavailability, respectively, necessitating close monitoring of therapeutic effects and adverse reactions. Renal impairment typically does not require dose adjustment unless severe. |
Safety & Warnings
Common Side Effects
- Verapamil hydrochloride, while generally well-tolerated, can cause a range of side effects, with severity and incidence often dose-dependent.
- The most frequently reported adverse effect is constipation, which can be significant in some patients.
- Other common side effects include headache, dizziness, nausea, fatigue, and peripheral edema.
- Less common but more serious adverse events involve the cardiovascular system and include hypotension, bradycardia, and various degrees of atrioventricular (AV) block (first, second, or third-degree), which can lead to syncope or, rarely, asystole.
- Verapamil can also exacerbate heart failure, particularly in patients with pre-existing left ventricular dysfunction, due to its negative inotropic effects.
- Other notable side effects may include gingival hyperplasia, liver enzyme elevations, and allergic skin reactions such as rash or pruritus.
- Patients should be educated on recognizing these side effects and reporting them to their healthcare provider for appropriate management, which may include dose adjustment or discontinuation.
Serious Warnings
- Black Box Warning: Although verapamil does not carry a formal FDA Black Box Warning, its use is associated with a significant risk of severe cardiovascular adverse events, particularly with intravenous administration or in susceptible patient populations, warranting a heightened level of clinical vigilance. There is a substantial risk of profound hypotension, severe bradycardia, and advanced atrioventricular (AV) block, which can critically impair cardiac output and lead to syncope, asystole, or cardiogenic shock. Extreme caution is mandated in patients with pre-existing severe left ventricular dysfunction (ejection fraction < 30%), as verapamil's negative inotropic effects can worsen heart failure. It is strictly contraindicated in patients with second- or third-degree AV block or sick sinus syndrome, unless a functioning artificial pacemaker is in place, due to the high risk of life-threatening conduction disturbances. Furthermore, verapamil must not be used in patients with atrial fibrillation or flutter when an accessory bypass tract (e.g., Wolff-Parkinson-White or Lown-Ganong-Levine syndromes) is present, as it can precipitate a rapid and potentially fatal ventricular tachyarrhythmia by facilitating conduction down the bypass tract. Concomitant intravenous administration of beta-blockers is absolutely contraindicated due to the additive depressant effects on cardiac conduction and contractility, which can lead to catastrophic cardiac events. Close monitoring of vital signs, cardiac rhythm via ECG, and overall clinical status is imperative throughout verapamil therapy, especially during initiation and dose adjustments in high-risk individuals.
- Verapamil hydrochloride requires careful use and monitoring due to its significant cardiovascular effects.
- It can cause severe hypotension, bradycardia, and advanced AV block, particularly with intravenous administration or in patients with pre-existing cardiac conduction abnormalities.
- Extreme caution is advised in patients with heart failure, especially those with moderate to severe left ventricular dysfunction, as verapamil’s negative inotropic effects can worsen cardiac function.
- Concomitant use with beta-blockers, particularly intravenously, is strongly discouraged due to additive effects on AV conduction and myocardial contractility, which can lead to profound bradycardia, heart block, or heart failure.
- Patients with atrial fibrillation or flutter and an accessory bypass tract (e.
- g.
- , Wolff-Parkinson-White syndrome) are at risk of developing life-threatening ventricular tachyarrhythmias if given verapamil, as it can accelerate conduction through the bypass tract.
- Dosage adjustment is essential in patients with hepatic impairment, as verapamil is extensively metabolized by the liver.
- Patients should be closely monitored for signs of excessive cardiac depression or hypotension, especially during initiation or dose escalation of therapy.
How it Works (Mechanism of Action)
Verapamil is a non-dihydropyridine calcium channel blocker that exerts its pharmacological effects by inhibiting the transmembrane influx of extracellular calcium ions across voltage-dependent L-type channels in cardiac and vascular smooth muscle cells. This action leads to several physiological consequences: In vascular smooth muscle, reduced intracellular calcium concentration results in relaxation and vasodilation, thereby decreasing systemic vascular resistance (afterload) and improving coronary blood flow, contributing to its antihypertensive and antianginal properties. In the heart, verapamil decreases myocardial contractility (negative inotropy) and slows atrioventricular (AV) nodal conduction. This negative inotropic effect reduces myocardial oxygen demand, further aiding in angina management. Its primary electrophysiological effect is to prolong the effective refractory period of the AV node and slow conduction through it, which is crucial for its antiarrhythmic efficacy in controlling ventricular rate in supraventricular tachyarrhythmias. Verapamil's selectivity for cardiac and AV nodal tissue, compared to its weaker effects on peripheral vasculature than dihydropyridines, defines its unique therapeutic profile.